A carregar...
A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects such as atrial fibrillation, bleedi...
Na minha lista:
| Publicado no: | Medeni Med J |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Istanbul Medeniyet University
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8226401/ https://ncbi.nlm.nih.gov/pubmed/34239769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5222/MMJ.2021.56424 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|